Literature DB >> 17208428

Jak2: normal function and role in hematopoietic disorders.

James N Ihle1, D Gary Gilliland.   

Abstract

Janus kinase 2 (Jak2) associates with cytokine receptors and is essential for signal transduction by mediating tyrosine phosphorylation. Kinase activity is regulated by a series of interactions beginning with the requirement to bind to specific domains in receptors, suppression of activation by the pseudokinase domain, and the requirement for phosphorylation within the activation loop. Recent studies have implicated de-regulation of Jak2 kinase activity by chromosomal translocations in hematopoietic tumors and mutations within the pseudokinase domain in a spectrum of myeloproliferative diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208428     DOI: 10.1016/j.gde.2006.12.009

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  57 in total

1.  BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.

Authors:  Oliver Hantschel; Wolfgang Warsch; Eva Eckelhart; Ines Kaupe; Florian Grebien; Kay-Uwe Wagner; Giulio Superti-Furga; Veronika Sexl
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

2.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

3.  A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.

Authors:  Eisaku Iwanaga; Tomoko Nanri; Naofumi Matsuno; Toshiro Kawakita; Hiroaki Mitsuya; Norio Asou
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

4.  Blockade of glioma proliferation through allosteric inhibition of JAK2.

Authors:  Kunyan He; Qi Qi; Chi-Bun Chan; Ge Xiao; Xia Liu; Carol Tucker-Burden; Liya Wang; Hui Mao; Xiang Lu; Frank E McDonald; Hongbo Luo; Qi-Wen Fan; William A Weiss; Shi-Yong Sun; Daniel J Brat; Keqiang Ye
Journal:  Sci Signal       Date:  2013-07-09       Impact factor: 8.192

Review 5.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

6.  Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Authors:  Sigal Gery; Qi Cao; Saskia Gueller; Hongtao Xing; Ayalew Tefferi; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2009-03-17       Impact factor: 4.962

7.  Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.

Authors:  Paul Collier; Keyur Patel; Paul Waeltz; Mark Rupar; Rajyalakshmi Luthra; Phillip C C Liu; Gregory Hollis; Reid Huber; Srdan Verstovsek; Timothy C Burn
Journal:  Genet Test Mol Biomarkers       Date:  2013-03-28

8.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

9.  Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock.

Authors:  Jixin Zhong; Ping Yang; Kenjiro Muta; Robert Dong; Mario Marrero; Feili Gong; Cong-Yi Wang
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

10.  Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.

Authors:  N Gefen; V Binder; M Zaliova; Y Linka; M Morrow; A Novosel; L Edry; L Hertzberg; N Shomron; O Williams; J Trka; A Borkhardt; S Izraeli
Journal:  Leukemia       Date:  2009-11-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.